Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients

Inclusion Criteria: * History of recurrent herpes labialis with at least two recurrences during the twelve months prior to the study. * Stable HIV infection * CD4+ T-cell count 100 to 500/mm3 Exclusion Criteria: * Systemic treatment with other antiviral agent or corticosteroids within two weeks prior to and during the treatment period, except for antiretroviral treatment in HIV subjects * Topical treatment with other antiviral agent or corticosteroids within in or around the oral area within two weeks prior to study drug administration * Significant skin condition that occur in the area typically affected by herpes recurrences * Nursing or pregnancy * Concurrent cancer therapy